Form 4: Allurion Technologies COO, Ojas Buch, Acquires Stock Options

Ojas Buch, Chief Operating Officer of Allurion Technologies, acquired stock options for 306,749 shares of common stock on June 3, 2024.

Summary

• On June 3, 2024, Ojas Buch, the Chief Operating Officer of Allurion Technologies, acquired stock options to purchase 306,749 shares of the company's common stock.
• The exercise price of these options is $1.43 per share.
• 25% of the shares underlying the option vest on June 3, 2025, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to the COO suggests confidence in the company's future, but it's a routine event.

Positives

• The acquisition of stock options by a key executive like the COO can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the COO, as the options vest over a period of several years.

Industry Context

Stock option grants are a common form of executive compensation in the technology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the technology and healthcare sectors.
• The vesting schedule of 25% after one year followed by monthly installments is a typical arrangement to incentivize long-term performance.
• Comparable companies in the medical device space, such as Intuitive Surgical or Medtronic, also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and potential future growth for the company.

Key Dates